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OBJECTIVE—An increase in the rate of hepatic glucose pro-
duction is the major determinant of fasting hyperglycemia in type
2 diabetes. A better understanding of the signaling pathways and
molecules that regulate hepatic glucose metabolism is therefore
of great clinical importance. Recent studies suggest that an
increase in vagal outﬂow to the liver leads to decreased hepatic
glucose production and reduced blood glucose levels. Since
acetylcholine (ACh) is the major neurotransmitter of the vagus
nerve and exerts its parasympathetic actions via activation of
muscarinic ACh receptors (mAChRs), we examined the potential
metabolic relevance of hepatocyte mAChRs.
RESEARCH DESIGN AND METHODS—We initially demon-
strated that the M3 mAChR is the only mAChR subtype expressed
by mouse liver/hepatocytes. To assess the physiological role of
this receptor subtype in regulating hepatic glucose ﬂuxes and
glucose homeostasis in vivo, we used gene targeting and trans-
genic techniques to generate mutant mice lacking or overex-
pressing M3 receptors in hepatocytes only.
RESULTS—Strikingly, detailed in vivo phenotyping studies
failed to reveal any signiﬁcant metabolic differences between the
M3 receptor mutant mice and their control littermates, indepen-
dent of whether the mice were fed regular or a high-fat diet.
Moreover, the expression levels of genes for various key tran-
scription factors, signaling molecules, and enzymes regulating
hepatic glucose ﬂuxes were not signiﬁcantly altered in the M3
receptor mutant mice.
CONCLUSIONS—This rather surprising ﬁnding suggests that
the pronounced metabolic effects mediated by activation of
hepatic vagal nerves are mediated by noncholinergic signaling
pathways. Diabetes 58:2776–2787, 2009
A
n increase in the rate of hepatic glucose pro-
duction is the major contributor to fasting
hyperglycemia in type 2 diabetes (1). A better
understanding of the signaling pathways and
molecules that regulate hepatic glucose metabolism is
therefore of high pathophysiological relevance.
Besides the well-known hepatic actions of the pancre-
atic hormones insulin and glucagon, hepatic glucose ﬂuxes
are regulated by several other hormones and neuro-
transmitters. For example, several studies suggest that
stimulation of hepatic parasympathetic (vagal) nerves
leads to reduced hepatic glucose output (2–4), in-
creased glycogen storage (5,6), and enhanced hepatic
glucose uptake (4,7,8). Consistent with these results,
acetylcholine (ACh), the principal neurotransmitter
stored in peripheral parasympathetic nerve endings, has
been shown to promote glycogen synthesis in isolated
rat hepatocytes (9,10).
Interestingly, a brain-liver circuit has been described
recently that is thought to be critical for maintaining
normal glucose homeostasis (11–13). In this circuit, in-
creased insulin and fatty acid levels are sensed in the
mediobasal hypothalamus, and the resulting activation of
central ATP-sensitive K
 channels eventually triggers an
increase in vagal outﬂow to the liver. This increased
activity of efferent hepatic vagal nerves results in de-
creased hepatic glucose production including reduced
gluconeogenesis, leading to a lowering of blood glucose
levels (11–13). A recent study (14) demonstrated that this
brain-liver circuit can also be activated by the direct
administration of lipids into the upper intestinal tract.
These studies led to the conclusion that any alterations
within this gut-brain-liver are likely to contribute to dia-
betic hyperglycemia.
The molecular nature of the hepatic receptors mediating
the striking metabolic effects following activation of
hepatic vagal nerves remains unknown at present. Fol-
lowing its release from vagal nerve endings, ACh acts
on distinct muscarinic ACh receptor subtypes (M1–M5
mAChRs) to regulate speciﬁc signaling pathways (15,16).
It seemed therefore reasonable to assume that mAChRs
play a key role in mediating the prominent changes in
glucose ﬂuxes seen after stimulation of vagal nerves
innervating the liver.
In this study, we initially demonstrated that the M3
mAChR is the only mAChR subtype expressed by mouse
liver/hepatocytes. To assess the physiological role of this
receptor subtype in regulating hepatic glucose ﬂuxes and
From the
1Molecular Signaling Section, Laboratory of Bioorganic Chemistry,
National Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health, Bethesda, Maryland; the
2Mouse Transgenic Core
Facility, National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health, Bethesda, Maryland; the
3Mammalian Genetics
Section, Genetics of Development and Diseases Branch, National Institute
of Diabetes and Digestive and Kidney Diseases, National Institutes of
Health, Bethesda, Maryland; the
4Departments of Medicine and Neuro-
science, Mount Sinai School of Medicine, New York, New York; and the
5Mouse Metabolic Core Facility, National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Corresponding author: Ju ¨rgen Wess, jwess@helix.nih.gov.
Received 8 April 2009 and accepted 2 September 2009. Published ahead of
print at http://diabetes.diabetesjournals.org on 14 September 2009. DOI:
10.2337/db09-0522.
S.-J.H. is currently afﬁliated with the Drug Biology Group, Institut Pasteur
Korea, Gyeonggi-Do, Korea.
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
2776 DIABETES, VOL. 58, DECEMBER 2009 diabetes.diabetesjournals.orgglucose homeostasis in vivo, we employed Cre/loxP tech-
nology to generate mutant mice lacking M3 receptors in
hepatocytes only. Moreover, to study the metabolic effects
of enhanced signaling through liver M3 mAChRs, we also
generated mutant mice selectively overexpressing this
receptor subtype in hepatocytes.
Interestingly, we found that the absence or overexpres-
sion of hepatocyte M3 mAChRs had little or no effect on
hepatic glucose ﬂuxes and glucose homeostasis in vivo.
These studies led to the surprising conclusion that the
pronounced metabolic effects mediated by activation of
the efferent vagal nerves innervating the liver are mediated
by signaling pathways that do not involve the activation of
hepatic mAChRs.
RESEARCH DESIGN AND METHODS
Mouse maintenance and diet. Mice were housed in a speciﬁc pathogen-free
barrier facility, maintained on a 12-h light/dark cycle. Unless indicated
otherwise, all experiments were carried out with male littermates maintained
on a C57BL/6 background. All experiments were approved by the animal care
and use committee of the National Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Generation of mutant mice selectively lacking or overexpressing M3
mAChRs in hepatocytes. M3 mAChR mutant mice selectively lacking or
overexpressing M3 mAChRs in hepatocytes (Hep-M3-KO and Hep-M3-Tg mice,
respectively) were generated as described under supplemental Methods in the
online appendix (available at http://diabetes.diabetesjournals.org/cgi/content/
full/db09-0522/DC1) (see also Fig. 1). Mouse genotypes were determined via
Southern blotting and/or PCR analysis using mouse tail DNA (see supplemen-
tal Methods for details).
Isolation of mouse hepatocytes and Kupffer cells. Mouse hepatocytes and
Kupffer cells were isolated from C57BL/6 mice (aged 2–3 months) (as
described in refs. 17 and 18, respectively).
Preparation of cDNA. Total RNA was extracted from various mouse tissues
using the QIAzol Lysis reagent (Qiagen). During total RNA preparation, an
on-column DNase I treatment step was performed (RNeasy Mini Kit; Qiagen).
For each sample, 1 g of RNA was reverse-transcribed into cDNA by using the
Superscript III ﬁrst-strand synthesis system for RT-PCR kit (Invitrogen).
RT-PCR analysis of mAChR expression in mouse liver. The expression of
M1–M5 receptor mRNA in liver and hepatocytes from wild-type mice (3-month-
old males; C57BL/6 background) was studied via RT-PCR, using cDNA
prepared as described above. The receptor subtype–speciﬁc PCR primers and
other experimental details have been described previously (19). The following
PCR conditions were used: 95°C for 30 s, followed by 37 cycles of 95°C for
10 s, 56°C for 40 s, and 72°C for 30 s.
RT-PCR analysis of M3 receptor transgene expression. cDNA prepared
from different tissues of Hep-M3-Tg mice was ampliﬁed via PCR using a primer
pair speciﬁc for the M3 receptor transgene (see supplemental Methods for
details).
Real-time quantitative RT-PCR analysis of gene expression. cDNA was
prepared from liver and other mouse tissues as described above. Gene
expression levels were measured by real-time quantitative RT-PCR (qRT-PCR)
analysis using an ABI 7900HT Fast Real-Time PCR System (Applied Biosys-
tems) (see supplemental Methods for details). Primer sequences are provided
in supplemental Table 2.
Radioligand binding studies with mouse liver membranes. For saturation
binding studies, mouse liver membrane preparations were incubated with
increasing concentrations (20 pmol/l–3 nmol/l) of [
3H]N-methylscopolamine
([
3H]NMS) (speciﬁc activity: 83 Ci/mmol; PerkinElmer), a non–subtype-
selective muscarinic antagonist, following a previously described protocol
(20). The preparation of mouse liver membranes is described in detail in the
supplemental Methods. Binding data were analyzed using the nonlinear
curve–ﬁtting program Prism 4.0 (GraphPad).
Determination of liver glycogen content. After extraction of glycogen
from mouse livers, glycogen was digested with amylase, and glucose concen-
trations were measured by a glucokinase radiometric assay (see supplemental
Methods for details).
Hormone and blood chemistry measurements. Blood glucose levels were
determined by using an automated blood glucose reader (Glucometer Elite
Sensor; Bayer). Serum insulin concentrations were determined via enzyme-
linked immunosorbent assay (Crystal Chem), and serum corticosterone,
norepinephrine, epinephrine, and glucagon levels were measured in freely fed
mice by the use of radioimmunoassay kits (corticosterone, MP Biomedicals;
norepinephrine and epinephrine, Rocky Mountain Diagnostics; glucagon,
Linco). Serum chemistry measurements were performed by the National
Institutes of Health Department of Laboratory Medicine.
Western blotting studies. Extracellular-regulated kinase (Erk) phosphory-
lation of mouse liver tissues was studied via Western blotting analysis, as
described in detail in the supplemental Methods.
In vivo physiological studies. Oral and intraperitoneal glucose tolerance
tests (OGTT and IGTT, respectively) were carried out with mice that had been
subjected to an overnight (12-h) fast. In the OGTT, mice were administered an
oral load of glucose (2 mg/g body wt) via oral gavage. In the IGTT, mice
received the same dose of glucose via intraperitoneal injection. In both tests,
blood samples were collected via retroorbital sinus puncture before (0 min)
and 15, 30, 60, and 120 min after glucose administration.
In insulin tolerance (sensitivity) tests, human insulin (0.75 units/kg; Eli
Lilly) was administered intraperitoneally to mice that had been fasted
overnight for 12 h. To obtain an estimate of gluconeogenesis in vivo, pyruvate
challenge tests (21) were performed in which mice deprived of food for 12 h
were injected intraperitoneally with sodium pyruvate (2 mg/g; Sigma). To
study the effect of glucagon on hepatic glucose production in vivo, mice were
fasted for 12 h and then injected intraperitoneally with human glucagon (16
g/kg) (22). Blood glucose levels were determined using blood obtained from
the tail vein just prior to (0 min) and at speciﬁc time points (up to 120 min)
after drug application.
Measurements of in vivo glucose kinetics and insulin clamp proce-
dures. Euglycemic clamps were performed in conscious, unrestrained, cath-
eterized mice as previously described (23) (see supplemental Methods for
details).
Body composition analysis. Body composition was determined by magnetic
resonance spectroscopy using an ECHO magnetic resonance spectroscopy
instrument (Echo Medical Systems, Houston, TX).
Statistical analysis. Data are expressed as means  SE for the indicated
number of observations. P values were calculated by using the appropriate t
tests.
RESULTS
RT-PCR analysis of mAChR expression in mouse
liver. Our initial goal was to determine which mAChR
subtypes are expressed in mouse liver (hepatocytes). To
address this question, we subjected total RNA prepared
from either whole liver or puriﬁed hepatocytes of wild-
type mice (C57BL/6 background) to RT-PCR ampliﬁcation
using mouse M1–M5 mAChR–speciﬁc primers (see RESEARCH
DESIGN AND METHODS for details). This analysis showed that
only M3 receptor cDNA could be detected in samples from
mouse liver and hepatocytes (Fig. 1A).
Generation of hepatocyte-speciﬁc M3 mAChR knock-
out mice. To examine the physiological relevance of
hepatocyte M3 mAChRs in vivo, we used Cre/loxP technol-
ogy to generate mutant mice that selectively lacked this
receptor subtype in hepatocytes (Fig. 1B–G) (for details,
see RESEARCH DESIGN AND METHODS). After EIIa-Cre–medi-
ated deletion of the neo gene (Fig. 1B–D), ﬂoxed M3
receptor mice in which the M3 receptor coding sequence
was ﬂanked by loxP sites (24) were crossed with AlbCre
transgenic mice that selectively express Cre recombi-
nase in hepatocytes (25). To generate mutant mice that
were homozygous for the ﬂoxed M3 receptor allele and
carried the AlbCre transgene (for the sake of simplicity,
these mice are referred to as Hep-M3-KO mice in the
following), we crossed M3 ﬂ/
 mice with M3 ﬂ/
 mice
that were hemizygous for the AlbCre transgene. This
mating strategy also produced three littermate control
groups: ﬂ/ﬂ,
/, and
/ AlbCre mice (Fig. 1E).
PCR and Southern blotting studies conﬁrmed that
AlbCre-mediated deletion of the M3 receptor gene had
occurred with high efﬁciency and selectivity in liver
genomic DNA prepared from Hep-M3-KO mice (Fig. 1E
and F). Real-time qRT-PCR studies indicated that he-
patic M3 receptor mRNA levels were reduced by 75%
in Hep-M3-KO mice, as compared with the correspond-
ing levels found with ﬂoxed control mice (Fig. 1G).
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diabetes.diabetesjournals.org DIABETES, VOL. 58, DECEMBER 2009 2777FIG. 1. Gene targeting strategy used to selectively delete the M3 mAChR gene in mouse hepatocytes. A: RT-PCR analysis of M1–M5 mAChR
expression in mouse liver, hepatocytes, and brain. Primers speciﬁc for the individual mouse mAChRs were used to amplify cDNA prepared from
wild-type mouse (C57BL/6 background) liver, hepatocyte, and brain total RNA. As expected, all ﬁve mAChR subtypes were found to be expressed
in the brain (positive control). In mouse liver, only M3 mAChR mRNA could be detected. RT, reverse transcriptase. B: Schematic representation
of the mouse M3 mAChR genomic locus, the conﬁguration of the ﬂoxed version of the M3 receptor gene, and the EIIa-Cre– and AlbCre-modiﬁed
alleles. The M3 receptor coding region is represented by the ﬁlled boxes. The approximate locations of the probes (ﬁlled bars) and primers
(arrows) used for Southern analysis and PCR genotyping studies, respectively, are shown. LoxP sites are depicted as black triangles. Relevant
restriction enzyme sites are indicated: E, EcoRV; S, SpeI, X, XhoI. C and D: Southern blotting strategy used to identify ﬂoxed M3 receptor mice
lacking the neo cassette due to EIIa-Cre–mediated deletion of the neo gene. For this analysis, EcoRV-digested mouse tail DNA was examined using
either probe 1 (C) or probe 2 (D). The 9.9-kb band indicates the presence of the ﬂoxed M3 receptor allele (ﬂ) lacking the neo gene (neo–),
whereas the 13.2- and 5.9-kb bands are diagnostic for the wild-type allele and the ﬂoxed M3 receptor allele carrying the neo gene (neo),
respectively. The following mouse genotypes were observed: lanes 1–3,M 3
ﬂ/,n e o ;l anes 4–6,M 3
ﬂ/ﬂ, neo; and lane 7, M3
ﬂ/,n e o . E: PCR analysis
of liver genomic DNA isolated from mice of the indicated genotypes. Cre indicates the presence of the AlbCre transgene. The location of the p1–p4
PCR primers is indicated in A. The Cre1 and Cre2 primers were used to detect the presence of the AlbCre transgene. The expected sizes of the
PCR products are indicated on the right. As expected, only liver DNA obtained from ﬂoxed M3 receptor mice harboring the AlbCre transgene gave
the 237-bp band (use of PCR primers p1 and p4; center panel), indicative of Cre-mediated deletion of the M3 receptor gene. The 230-bp (upper
panel) and 310-bp (lower panel) PCR products are diagnostic for the 5 and 3 loxP sites, respectively (the 196- and 276-bp bands correspond to
wild-type sequence). F: Southern blotting strategy used to demonstrate the deletion of the M3 receptor gene in the liver of ﬂoxed M3 receptor
mice carrying the AlbCre transgene. Mouse genomic DNA that had been digested with SpeI was subjected to Southern blotting analysis using
probe 2 (see B). Lanes 1 and 2: Genomic DNA isolated from the liver of M3
ﬂ/ﬂ mice. Lanes 3–5: Genomic DNA isolated from the liver of M3
ﬂ/ﬂ mice
carrying the AlbCre transgene. Lanes 6–8: Genomic DNA isolated from brain (lane 6), ileum (lane 7), or submandibular gland (subm. gland)
(lane 8)o fM 3
ﬂ/ﬂ mice carrying the AlbCre transgene. The 12.6-kb band is diagnostic for the presence of the ﬂoxed M3 receptor allele, whereas
the 8.3-kb band indicates that AlbCre-mediated deletion of the M3 receptor gene has occurred. G: qRT-PCR analysis indicating greatly reduced
M3 receptor mRNA expression in the liver of M3
ﬂ/ﬂ mice carrying the AlbCre transgene. Real-time qRT-PCR studies were carried out using total
RNA prepared from the indicated tissues of M3
ﬂ/ﬂ AlbCre mice and control (M3
ﬂ/ﬂ) littermates (7-month-old males, n  3). Data were normalized
relative to expression levels observed with the control mice (100%). Cyclophilin A served as an internal control. **P < 0.01 vs. control.
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labeled with [
3H]NMS, a non–subtype-selective musca-
rinic antagonist (data not shown). In contrast, M3 recep-
tor mRNA expression was comparable between Hep-
M3-KO mice and control littermates in other tissues
(brain, ileum, or submandibular gland), where M3 recep-
tors are known to be expressed at physiologically
relevant levels (15,16) (Fig. 1G). The small population
of hepatic M3 mAChRs/transcripts remaining in Hep-
M3-KO mice may be due to residual M3 receptor expres-
sion in nonhepatocyte liver cells (note that 85% of
liver cells represent hepatocytes).
All mice were born at the expected Mendelian frequency,
and the body weight of the Hep-M3-KO mice did not
differ signiﬁcantly from that of the three control groups
(data not shown). Moreover, Hep-M3-KO mice were
fertile and showed no obvious developmental, behav-
ioral, or morphological deﬁcits. Hep-M3-KO mice and
their control littermates showed similar serum levels in
hepatic enzymes, cholesterol, albumin, total protein,
and uric acid (supplemental Table 2), suggesting that
overall liver function was not affected by the lack of
hepatocyte M3 receptors. Similarly, the lack of hepatic
M3 receptors had no obvious effects on liver histology in
FIG. 2. Physiological analysis of Hep-M3-KO mice (f) and control littermates () maintained on regular diet. A: Growth curves of male mice. B:
Body composition (4-month-old males; control, n  9; Hep-M3-KO, n  6). C: Fed and fasting blood glucose. D: Serum insulin levels of Hep-M3-KO
mice and control littermates. Blood samples were taken from freely fed mice or from mice that had been fasted for 12 h (3- and 8-month-old males;
n  7–9 per group). E: Insulin clamp studies. Rates of glucose uptake (RD, glucose disposal), GIR, and endogenous glucose production (GP) are
indicated (4-month-old males; n  3 per group). F: Blood glucose levels following intraperitoneal administration of 2 mg/g of glucose (IGTT;
16-week-old males, n  6 per group). G: Blood glucose levels following oral administration of 2 mg/g of glucose (OGTT; 20-week-old males, n 
6 per group). H: Insulin tolerance test (ITT). Blood glucose levels were measured at the indicated time points after intraperitoneal injection of
0.75 units/kg of insulin (18-week-old males, n  6 per group). I: Glucagon tolerance test. Blood glucose levels were measured at the indicated time
points after intraperitoneal injection of 16 g/kg of glucagon (18-week-old males, n  6 per group). J: Pyruvate challenge test. Blood glucose
levels were measured at the indicated time points after intraperitoneal injection of 2 mg/g of sodium pyruvate (22-week-old males, n  6 per
group). *P < 0.05 vs. control.
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studies (data not shown).
The lack of hepatic M3 receptors has little or no
obvious metabolic consequences in vivo. We initially
conducted a series of metabolic studies using Hep-M3-KO
mice and control littermates (M3 ﬂ/ﬂ mice) maintained on
regular mouse diet. The two mouse strains did not show
any signiﬁcant differences in body weight and composition
(Fig. 2A and B), as well as fed and fasting blood glucose
and serum insulin levels (measured in 3- and 8-month-old
males) (Fig. 2C and D).
To investigate whether the Hep-M3-KO mice exhibited
changes in glucose tolerance, we carried out OGTTs and
IGTTs (glucose dose: 2 mg/g body wt). In both tests,
Hep-M3-KO mice and their control littermates displayed
similar increases in blood glucose levels throughout the
entire 2-h observation period (Fig. 2F and G), except for a
slight decrease in glucose levels in Hep-M3-KO mice in the
OGTT at the 30-min time point. Similarly, both groups of
mice showed comparable decreases in blood glucose
levels in an insulin tolerance test (insulin dose: 0.75
units/kg i.p.) (Fig. 2H).
To reveal potential differences in hepatic glucose pro-
duction in vivo, we injected Hep-M3-KO mice and control
littermates with glucagon (16 g/kg i.p.) and monitored
changes in blood glucose levels for a 1-h period (22). The
main action of glucagon is to stimulate hepatic glucose
production by increasing glycogenolysis and gluconeogen-
esis while inhibiting glycogen synthesis (26). Figure 2I
clearly shows that Hep-M3-KO mice and control litter-
mates displayed identical increases in blood glucose levels
in this glucagon challenge test.
To examine whether the lack of hepatic M3 receptors
affected gluconeogenesis in vivo, we injected Hep-M3-KO
mice and control littermates with the gluconeogenic sub-
strate pyruvate (2 mg/g i.p.) and monitored changes in
blood glucose levels over a 2-h period (pyruvate challenge
test) (21). We found that the observed increases in blood
glucose levels did not differ signiﬁcantly between the two
groups of mice (Fig. 2J).
To further examine whether the lack of hepatocyte M3
receptors affected glucose ﬂuxes in vivo, we carried out
insulin clamp studies using Hep-M3-KO mice and control
littermates maintained on standard diet (4-month-old
males). The glucose infusion rate (GIR) was adjusted in
order to maintain blood glucose concentrations in both
groups of mice at similar levels (8 mmol/l), while insulin
was infused at a rate of 3.6 mU  kg
1  min
1 to generate
a physiological increase in plasma insulin levels (8
ng/ml). All measurements were performed during the ﬁnal
40 min of the 90-min clamp procedure, after steady-state
conditions for plasma glucose and insulin concentrations,
glucose-speciﬁc activity, and rates of glucose infusion
were achieved. The GIR required to prevent the mice from
developing hypoglycemia was not signiﬁcantly different
between Hep-M3-KO mice and control littermates (Fig.
FIG. 3. Liver weight, glycogen content, and gene expression analysis of Hep-M3-KO mice (f) and control littermates () maintained on regular
diet. A: Liver weight. B: Liver glycogen content of Hep-M3-KO mice and control littermates (freely fed 8-month-old males, n  6 per group). C:
Liver gene expression analysis. Gene expression was studied by real-time qRT-PCR using total hepatic RNA prepared from Hep-M3-KO mice and
control littermates (freely fed 3-month-old males). Data from three independent experiments were normalized relative to the expression of
cyclophilin A, which served as an internal control. Results are presented as percent change in gene expression in Hep-M3-KO mice relative to
control littermates (100%). Acly, ATP citrate lyase; AOX, acyl-CoA oxidase; CPT, carnitine palmitoyltransferase; CREB, cAMP-response element
binding protein; FAS, fatty acid synthase; GK, glucokinase; IR, insulin receptor; IRS1, IR substrate 1; PC, pyruvate carboxylase; PGC, PPAR
coactivator; PPAR, peroxisome proliferator–activated receptor.
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the rate of endogenous glucose production (net increase in
glucosyl units derived from gluconeogenesis and glycogen-
olysis) did not differ signiﬁcantly between the two mouse
strains (Fig. 2E). Liver weight and liver glycogen content
did not differ signiﬁcantly between freely fed Hep-M3-KO
mice and their control littermates (Fig. 3A and B).
Liver gene expression analysis in Hep-M3-KO mice.
We next used real-time qRT-PCR to study whether the
expression of genes for various key transcription factors,
FIG. 4. Physiological analysis of Hep-M3-KO mice (f) and control
littermates () maintained on a high-fat diet. A: Growth curves. B:
Fed blood glucose levels of male mice maintained on a high-fat diet
(n  7–9 per group). C: Blood glucose levels following intraperitoneal
administration of 2 mg/g of glucose (IGTT; 16-week-old males, n  6
per group). D: Blood glucose levels following oral administration of 2
mg/g of glucose (OGTT; 20-week-old males, n  6 per group). E:
Insulin tolerance test (ITT). Blood glucose levels were measured at
the indicated time points after intraperitoneal injection of 0.75
units/kg of insulin (18-week-old males, n  6 per group). F: Glucagon
tolerance test. Blood glucose levels were measured at the indicated
time points after intraperitoneal injection of 16 g/kg of glucagon
(18-week-old males, n  6 per group). G: Pyruvate challenge test.
Blood glucose levels were measured at the indicated time points after
intraperitoneal injection of 2 mg/g of sodium pyruvate (22-week-old
males, n  6 per group). *P < 0.05 vs. control.
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cose ﬂuxes and other metabolic functions were altered in
Hep-M3-KO mice (freely fed). The genes studied included
those coding for phosphoenolpyruvate carboxykinase
(PEPCK) and glucose-6-phosphatase (G6Pase), the two
key enzymes regulating the rate of gluconeogenesis. This
analysis did not reveal any signiﬁcant differences in liver
gene expression levels between Hep-M3-KO mice and
control littermates (Fig. 3C).
Physiological studies with Hep-M3-KO mice main-
tained on a high-fat diet. Several studies have shown
that the consumption of a high-fat diet triggers an increase
in the activity of the parasympathetic nervous system in
mice (27,28). We therefore speculated that the resulting
increase in ACh release from peripheral parasympathetic
nerves may lead to enhanced signaling through hepatic M3
mAChRs, potentially unmasking a critical metabolic role
for these receptors in Hep-M3-KO mice.
Speciﬁcally, Hep-M3-KO mice and their control litter-
mates (5-week-old males) were fed a high-fat diet (fat
content: 35.5%, wt/wt) and then monitored for an 8-week
period. As expected, the consumption of the high-fat diet
triggered rapid weight gain (Fig. 4A), hyperglycemia (Fig.
4B), impaired glucose tolerance (IGTT, Fig. 4C; OGTT, Fig.
4D), and insulin resistance (Fig. 4E) in the control mice.
Interestingly, Hep-M3-KO mice showed very similar meta-
bolic deﬁcits in all of these tests (Fig. 4A–E), except for a
slight reduction in blood glucose levels in the OGTT at the
60-min time point (Fig. 4D). Hep-M3-KO mice and their
control littermates also showed very similar increases in
blood glucose levels in the glucagon and pyruvate chal-
lenge tests (Fig. 4F and G).
Generation of transgenic mice selectively overex-
pressing M3 mAChRs in hepatocytes. To examine the
possible metabolic consequences of enhanced signaling
through hepatic M3 mAChRs, we generated transgenic
mice that selectively overexpressed this receptor subtype
in hepatocytes. To ensure that M3 receptors were selec-
tively expressed by hepatocytes, transgene expression was
placed under the control of the mouse albumin promoter/
enhancer (29). By using standard transgenic techniques (see
RESEARCH DESIGN AND METHODS), we obtained several mutant
mouse lines that had stably incorporated the M3 receptor
transgene into their genomes.
To quantitate the number of M3 receptors overex-
pressed in hepatocytes of the different transgenic lines,
we incubated mouse liver membranes with a saturating
concentration (2 nmol/l) of the muscarinic antagonist,
[
3H]NMS. Control experiments with wild-type littermates
showed that endogenous liver mAChRs were expressed at
a density of 15.3  4.0 fmol/mg membrane protein (n  3;
3-month-old males). Interestingly, one of the analyzed
transgenic lines, referred to as Hep-M3-Tg in the following,
showed a pronounced (approximately fourfold) increase
in hepatic mAChR density (61.6  2.4 fmol/mg membrane
protein; n  3; 3-month-old males). Consistent with these
results, qRT-PCR studies demonstrated that Hep-M3-Tg
mice displayed a striking increase in hepatic M3 receptor
mRNA expression levels compared with wild-type litter-
mates (Fig. 5A). RT-PCR studies using total RNA prepared
from several peripheral and central tissues conﬁrmed that
the M3 receptor transgene was selectively expressed in the
liver of Hep-M3-Tg mice (Fig. 5B). For these reasons, the
Hep-M3-Tg mouse line was selected and ampliﬁed for
more detailed physiological studies.
Overexpression of hepatic M3 receptors has no sig-
niﬁcant metabolic effects in vivo. Hep-M3-Tg mice
were subjected to the same set of physiological studies
as Hep-M3-KO mice (see above). Hep-M3-Tg mice ap-
peared healthy and showed no obvious behavioral or
morphological abnormalities. Moreover, the body weight of
Hep-M3-Tg mice maintained on regular mouse chow did not
differ signiﬁcantly from that of their wild-type littermates
(Fig. 6A).
Hep-M3-Tg and wild-type control mice consuming regu-
lar mouse diet showed similar fed and fasting blood
glucose and serum insulin levels (measured in 3- and
9-month-old males) (Fig. 6B and C). Moreover, in both
OGTTs and IGTTs (glucose dose: 2 mg/g body wt), Hep-
M3-Tg and wild-type control mice exhibited similar
changes in blood glucose levels throughout the entire 2-h
observation period (16- to 18-week-old males; Fig. 6D and
E). Likewise, Hep-M3-Tg and wild-type control mice dis-
played comparable glucose responses in insulin, glucagon,
and pyruvate tolerance/challenge tests (16- to 20-week-old
males) (Fig. 6F–H).
As shown in Fig. 7A and B, liver weight and liver
glycogen content did not differ signiﬁcantly between Hep-
M3-Tg mice and their wild-type littermates (freely fed).
Moreover, real-time qRT-PCR studies did not reveal any
signiﬁcant differences in liver gene expression levels be-
tween freely fed Hep-M3-Tg mice and wild-type littermates
(Fig. 7C).
FIG. 5. Liver-speciﬁc overexpression of M3 mAChRs in Hep-M3-Tg
mice. A: Real-time qRT-PCR analysis of M3 receptor mRNA expression
in the liver of Hep-M3-Tg and wild-type (WT) control mice. qRT-PCR
experiments were carried out with mouse liver cDNA as described
under supplemental Methods, using a primer pair that ampliﬁes both
the M3 receptor transgene and native M3 receptor transcripts (supple-
mental Table 1; n  5 per group; mouse age 12 weeks). The mRNA
expression levels displayed by liver samples prepared from WT mice
were set equal to 100%. B: RT-PCR analysis of M3 mAChR transgene
expression in different tissues from Hep-M3-Tg mice. RT-PCR experi-
ments were performed as described under supplemental Methods using
an M3 receptor transgene-speciﬁc primer pair (size of the PCR product:
405 bp). As expected, transgene expression was found to be liver
speciﬁc. Control samples (indicated by the minus signs above the
lanes) that had not been treated with reverse transcriptase (RT) did
not give any detectable signal, conﬁrming the absence of contaminat-
ing genomic DNA. Hypoth., hypothalamus; Subm., submandibular.
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ceptors had any effect on the metabolic deﬁcits associated
with the chronic consumption of a high-fat diet, Hep-
M3-Tg mice and their control littermates (5-week-old males)
were fed a high-fat diet (fat content: 35.5%, wt/wt) and then
monitored for a 14-week period. Wild-type littermates main-
tained on the high-fat diet showed rapid weight gain (Fig.
8A), hyperglycemia (Fig. 8B), impaired glucose tolerance
(IGTT, Fig. 8C; OGTT, Fig. 8D), and insulin resistance (Fig.
8E). In all of these tests, Hep-M3-Tg mice displayed meta-
bolic phenotypes that were not signiﬁcantly different from
those observed with the wild-type control mice (Fig. 8A–E).
Hep-M3-Tg mice and their wild-type littermates also exhib-
ited virtually identical glucose responses in the glucagon and
pyruvate challenge tests (Fig. 8F and G).
Additional hormone and hepatic Erk measurements
in Hep-M3-KO and Hep-M3-Tg mutant mice and con-
trol littermates. To examine whether glucose-dependent
insulin release was altered by the lack or overexpression
of hepatic M3 receptors, fasted Hep-M3-KO and Hep-M3-Tg
mutant mice and their corresponding control littermates
received an oral glucose load (2 mg/g; 18- to 20-week-old
males). For these studies, we used mice maintained on
either regular or a high-fat diet. Serum insulin levels
were monitored 15, 30, 60, and 120 min after glucose
administration. This analysis showed that glucose-in-
duced insulin release was not signiﬁcantly affected by
the lack or overexpression of hepatic M3 receptors
(supplemental Fig. 1).
To exclude the possibility that the activity of the
sympathetic nervous system was altered in the M3
receptor mutant mice, we measured serum norepineph-
rine and epinephrine levels in Hep-M3-KO and Hep-
M3-Tg mutant mice and control littermates (freely fed
2-month-old males). We found that serum norepineph-
rine and epinephrine levels did not differ signiﬁcantly
between M3 receptor mutant mice and their correspond-
ing control mice (supplemental Table 3).
We also found that the serum levels of corticosterone
and glucagon, two of the key hormones counteracting the
glucose-lowering effects of insulin, did not differ signiﬁ-
cantly between M3 receptor mutant mice and their corre-
sponding control mice (freely fed 2-month-old males;
supplemental Table 3).
A recent study demonstrated that hepatic stimulation
of Erk led to the activation of a relay of neuronal
pathways resulting in increased pancreatic -cell prolif-
eration and enhanced glucose-induced insulin secretion
(30). We therefore examined whether Erk phosphoryla-
tion was altered in the livers of Hep-M3-KO and Hep-
M3-Tg mutant mice (freely fed 2-month-old males).
However, Western blotting experiments demonstrated
that the M3 receptor mutant mice did not show any
signiﬁcant changes in hepatic Erk phosphorylation com-
FIG. 6. Physiological analysis of Hep-M3-Tg mice (f)
and wild-type (WT) littermates () maintained on
regular diet. A: Growth curves of male mice. B: Fed
and fasting blood glucose. C: Serum insulin levels of
Hep-M3-Tg and WT control mice maintained on regu-
lar diet. Blood samples were taken from freely fed
mice or from mice that had been fasted for 15 h (3-
and 9-month-old males; n  7–9 per group). Hep-
M3-Tg mice (f) and WT control littermates (). D:
Blood glucose levels following intraperitoneal admin-
istration of 2 mg/g of glucose (IGTT; 16-week-old
males, n  6 per group). E: Blood glucose following
oral administration of 2 mg/g of glucose (OGTT;
20-week-old males, n  6 per group). F: Insulin
tolerance test (ITT). Blood glucose levels were mea-
sured at the indicated time points after intraperitoneal injection of 0.75 units/kg of insulin (16-week-old males, n  7 per group). G: Glucagon
tolerance test. Blood glucose levels were measured at the indicated time points after intraperitoneal injection of 16 g/kg of glucagon
(20-week-old males, n  7 per group). H: Pyruvate challenge test. Blood glucose levels were measured at the indicated time points after
intraperitoneal injection of 2 mg/g of sodium pyruvate (18-week-old males, n  7 per group). Hep-M3-Tg mice (f) and WT littermates ().
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plemental Fig. 2).
Lack of M3 receptor expression in Kupffer cells. To
examine whether M3 receptors were expressed by non-
parenchymal liver cells, we used RT-PCR to study M3
receptor expression in Kupffer cells prepared from adult
wild-type mice (C57BL/6 mice). This analysis failed to
detect M3 receptor mRNA in mouse Kupffer cells (supple-
mental Fig. 3). On the other hand, F4/80 mRNA that codes
for a Kupffer cell-speciﬁc glycoprotein was readily detect-
able in both Kupffer cell preparations used (supplemental
Fig. 3).
DISCUSSION
ACh, the major neurotransmitter released from efferent
vagal nerve endings, mediates its physiological actions via
stimulation of distinct mAChR subtypes (15,16). Recent
studies (11–14) suggest that the activity of efferent hepatic
vagal nerves is critical for maintaining normal glucose
homeostasis.
In this study, we found that the M3 mAChR is the only
mAChR subtype expressed by mouse liver or hepatocytes,
consistent with a previous study examining the pattern of
mAChR subtype expression in rat hepatocytes (10). To
examine the potential metabolic relevance of hepatocyte
M3 mAChRs, we used Cre/loxP technology to generate
mutant mice lacking M3 receptors in hepatocytes only
(Hep-M3-KO mice). In parallel, we also generated and
analyzed transgenic mice that overexpressed M3 mAChRs
selectively in hepatocytes (Hep-M3-Tg mice). Surprisingly,
detailed in vivo phenotyping studies failed to detect any
signiﬁcant metabolic differences between Hep-M3-KO or
Hep-M3-Tg mice and their control littermates. Consistent
with this observation, qRT-PCR studies showed that the
lack or overexpression of hepatic M3 mAChRs had no
signiﬁcant effect on the hepatic expression of PEPCK and
G6Pase, the two key enzymes regulating the rate of
gluconeogenesis, and of various key transcription factors,
signaling molecules, and enzymes regulating hepatic glu-
cose ﬂuxes. Similarly, euglycemic-hyperinsulinemic clamp
studies did not reveal any signiﬁcant differences in glucose
ﬂuxes between Hep-M3-KO mice and their control litter-
mates. Thus, the presence of hepatocyte M3 receptors is
not required for the ability of insulin to suppress hepatic
glucose production.
The consumption of a high-fat diet is known to trigger
an increase in the activity of the parasympathetic nervous
system in mice (27,28). Moreover, the intake of a high-fat
diet usually leads to increased levels of plasma lipids and
insulin, due to rapid development of insulin resistance. As
discussed above, accumulating evidence indicates that
increased plasma lipid and insulin levels are monitored in
the mediobasal hypothalamus (11–13), triggering an in-
crease in vagal outﬂow to the liver, followed by inhibition
of hepatic glucose production and lowering of blood
glucose levels. We therefore speculated that changes in
the activity of hepatic M3 mAChRs might lead to altered
glucose homeostasis in Hep-M3-KO or Hep-M3-Tg mice.
For example, since the M3 mAChR is the only mAChR
subtype detectable in mouse hepatocytes, we hypothe-
FIG. 7. Liver weight, glycogen content, and gene expression analysis of Hep-M3-Tg mice (f) and wild-type (WT) control mice () maintained on
a regular diet. A: Liver weight. B: Liver glycogen content of Hep-M3-Tg mice and control littermates (freely fed 8-month-old males, n  6 per
group). C: Liver gene expression analysis. Gene expression was studied by real-time qRT-PCR using total hepatic RNA prepared from Hep-M3-Tg
mice and WT littermates (freely fed 3-month-old males). Data from three independent experiments were normalized relative to the expression
of cyclophilin A, which served as an internal control. Results are presented as percent change in gene expression in Hep-M3-Tg mice relative to
WT control mice (100%). For full gene names, see the legend to Fig. 3.
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in Hep-M3-Tg mice would be associated with beneﬁcial
effects on whole-body glucose homeostasis, due to inhibi-
tion of hepatic glucose production. However, a series of in
vivo studies carried out with Hep-M3-KO and Hep-M3-Tg
mice maintained on a high-fat diet showed that the M3
receptor mutant mice and their control littermates showed
quantitatively similar metabolic deﬁcits, including in-
creased blood glucose levels, impaired glucose tolerance,
and insulin resistance. Taken together, these observations
lead to the surprising conclusion that hepatocyte (M3)
mAChRs do not play a critical role in maintaining proper
glucose homeostasis in vivo.
Consistent with the in vivo results discussed above,
incubation of primary mouse or rat hepatocytes with ACh
or the hydrolytically stable ACh derivative, carbachol, had
no signiﬁcant effect on glucose production in vitro (C.B.,
unpublished data). One possible explanation for our ﬁnd-
ings is that other neurotransmitters or neuromodulators,
which are coreleased with ACh following vagal stimula-
tion, are responsible for the vagus-mediated suppression
of hepatic glucose production. For example, several neu-
FIG. 8. Physiological analysis of Hep-M3-Tg mice (f) and wild-type
(WT) littermates () maintained on a high-fat diet. A: Growth curves.
B: Fed blood glucose levels of male mice maintained on a high-fat diet
(n  7–9 per group). C: Blood glucose levels following intraperitoneal
administration of 2 mg/g of glucose (IGTT; 16-week-old males, n  6
per group). D: Blood glucose levels following oral administration of 2
mg/g of glucose (OGTT); 18-week-old males, n  6 per group). E:
Insulin tolerance test (ITT). Blood glucose levels were measured at
the indicated time points after intraperitoneal injection of 0.75
units/kg of insulin (20-week-old males, n  7 per group). F: Glucagon
tolerance test. Blood glucose levels were measured at the indicated
time points after intraperitoneal injection of 16 g/kg of glucagon
(22-week-old males, n  7 per group). G: Pyruvate challenge test.
Blood glucose levels were measured at the indicated time points after
intraperitoneal injection of 2 mg/g of sodium pyruvate (14-week-old
males, n  7 per group).
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gastrin-releasing peptide, and pituitary adenylate cyclase–
activating peptide, as well as nitric oxide (NO), are known
to be coreleased with ACh from peripheral parasympa-
thetic nerve endings (27,28). Interestingly, Horton et al.
(31) previously demonstrated that NO exerts a strong
inhibitory effect on hepatic gluconeogenesis in isolated rat
hepatocytes.
Another possibility is that ACh, following its release
from hepatic vagal nerve endings, does not act primarily
on hepatocytes but on nonparenchymal cells like Kupffer
or hepatic stellate cells that subsequently cause the re-
lease of one or more other signaling molecules such as
prostaglandins (32) or cytokines (33) that affect hepato-
cyte function in a paracrine fashion. Interestingly, a recent
study (34) showed that activation of central insulin receptors
results in the release of interleukin-6 (IL-6) from nonparen-
chymal liver cells resembling Kupffer cells, most likely due to
stimulation of efferent hepatic nerves. In addition, the au-
thors demonstrated that the paracrine release of IL-6 trig-
gered the activation of STAT3, leading to the suppression of
hepatic glucose production (34). However, we showed in the
present study that mouse Kupffer cells do not express M3
receptors, excluding the possibility that mAChRs play a role
in insulin-induced hepatic IL-6 release.
In conclusion, our data convincingly demonstrate that
hepatic mAChRs do not play a critical role in maintaining
proper glucose homeostasis in mice. Since the activity of
efferent hepatic vagal nerves is predicted to be critically
involved in maintaining normal blood glucose levels (11–
14), the identiﬁcation of other (nonmuscarinic) hepatic
signaling pathways that are under vagal control may lead
to novel strategies to modulate hepatic glucose ﬂuxes for
therapeutic purposes.
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